In conclusion, taking advantage of the ease of cell internalization and the slow drug release of PGNP nanoconjugates, we effectively prevented Pgp overexpression in drug-sensitive cancer cells after long-term treatment, indicating the possibility of long-term or repeated nanodrug use without induction of drug resistance. This evidence concerns the gene PGP and cancer.